<DrugInformationSummary id="CDR0000767622"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Olaparib works by blocking the activity of PARP enzymes, which help repair damaged DNA in cells. Cancer cells with BRCA mutations or certain other gene mutations cannot use a key DNA repair process called homologous recombination (HR) and need PARP enzymes to survive. Blocking the activity of PARP enzymes causes these cancer cells to die. Olaparib is a type of targeted therapy drug called a PARP inhibitor. It is a small-molecule drug (a drug that can enter cells easily).</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/olaparib">Olaparib</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000560191">olaparib</TerminologyLink><GlossaryLink ref="CDR0000657862">olaparib</GlossaryLink><USBrandNames><USBrandName>Lynparza</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>oh-LA-puh-rib</TermPronunciation><MediaLink ref="CDR0000725752" type="audio/mpeg" alt="" language="en" id="_5"/><MediaLink ref="CDR0000725751" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Olaparib</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Olaparib
         is approved 
         to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000774531" dictionary="Cancer.gov" audience="Patient">HER2 negative</GlossaryTermRef> and has certain <GlossaryTermRef href="CDR0000046384" dictionary="Cancer.gov" audience="Patient">germline mutations</GlossaryTermRef> in the <GeneName><GlossaryTermRef href="CDR0000046047" dictionary="Cancer.gov" audience="Patient">BRCA1</GlossaryTermRef></GeneName> or <GeneName><GlossaryTermRef href="CDR0000046742" dictionary="Cancer.gov" audience="Patient">BRCA2</GlossaryTermRef></GeneName> gene. Olaparib is used after surgery in adults with:<ItemizedList Style="bullet" id="_6"><ListItem>high-risk <GlossaryTermRef href="CDR0000446564" dictionary="Cancer.gov" audience="Patient">early-stage breast cancer</GlossaryTermRef> that has been treated with chemotherapy before or after surgery</ListItem><ListItem><GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">metastatic</GlossaryTermRef> cancer that has been treated with chemotherapy before or after the cancer  spread</ListItem></ItemizedList></ListItem>
   
   <ListItem><Strong><GlossaryTermRef href="CDR0000046768" dictionary="Cancer.gov" audience="Patient">Ovarian epithelial</GlossaryTermRef>,</Strong> <Strong><GlossaryTermRef href="CDR0000755773" dictionary="Cancer.gov" audience="Patient">fallopian tube</GlossaryTermRef>,</Strong> or <Strong><GlossaryTermRef href="CDR0000386215" dictionary="Cancer.gov" audience="Patient">primary peritoneal cancer</GlossaryTermRef>.</Strong> Olaparib is used as <GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">maintenance therapy</GlossaryTermRef> in adults who are  having a <GlossaryTermRef href="CDR0000045652" dictionary="Cancer.gov" audience="Patient">complete</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045819" dictionary="Cancer.gov" audience="Patient">partial response</GlossaryTermRef> to <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef> chemotherapy. It is used:<ItemizedList Style="bullet" id="_5"><ListItem>as the first maintenance therapy in patients with advanced cancer that has certain germline or <GlossaryTermRef href="CDR0000046586" dictionary="Cancer.gov" audience="Patient">somatic mutations</GlossaryTermRef> in the <GeneName>BRCA1</GeneName> or <GeneName>BRCA2</GeneName> gene</ListItem><ListItem>with <GlossaryTermRef href="CDR0000046115" dictionary="Cancer.gov" audience="Patient">bevacizumab</GlossaryTermRef> as the first maintenance therapy in patients with advanced cancer that has <GlossaryTermRef href="CDR0000800171" dictionary="Cancer.gov" audience="Patient">genomic instability</GlossaryTermRef> and/or certain germline or somatic mutations in the <GeneName>BRCA1</GeneName> or <GeneName>BRCA2</GeneName> gene</ListItem><ListItem>in patients with <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> cancer</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044521" dictionary="Cancer.gov" audience="Patient">Pancreatic cancer</GlossaryTermRef>.</Strong> Olaparib is used as maintenance therapy in adults with metastatic cancer that has not <GlossaryTermRef href="CDR0000044078" dictionary="Cancer.gov" audience="Patient">progressed</GlossaryTermRef> after first-line therapy with platinum chemotherapy and has certain germline mutations in the <GeneName>BRCA1</GeneName> or <GeneName>BRCA2</GeneName> gene.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000445079" dictionary="Cancer.gov" audience="Patient">Prostate cancer</GlossaryTermRef></Strong> that has spread to other parts of the body and is <GlossaryTermRef href="CDR0000753525" dictionary="Cancer.gov" audience="Patient">castrate resistant</GlossaryTermRef> (has not responded to treatments that lower <GlossaryTermRef href="CDR0000045581" dictionary="Cancer.gov" audience="Patient">testosterone</GlossaryTermRef> levels). Olaparib is used:<ItemizedList Style="bullet" id="_7"><ListItem>alone in adults with germline or somatic mutations in certain genes involved in the <GlossaryTermRef href="CDR0000801714" dictionary="Cancer.gov" audience="Patient">homologous
recombination repair pathway</GlossaryTermRef> whose cancer has gotten worse after treatment  with <GlossaryTermRef href="CDR0000740024" dictionary="Cancer.gov" audience="Patient">enzalutamide</GlossaryTermRef> or <GlossaryTermRef href="CDR0000641969" dictionary="Cancer.gov" audience="Patient">abiraterone</GlossaryTermRef></ListItem><ListItem>with abiraterone and <GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046155" dictionary="Cancer.gov" audience="Patient">prednisolone</GlossaryTermRef> in adults with certain mutations in the <GeneName>BRCA1</GeneName> or <GeneName>BRCA2</GeneName> gene</ListItem></ItemizedList> </ListItem></ItemizedList>
  <Para id="_4">Olaparib
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Olaparib</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/560191">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.18">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a614060.html">Olaparib</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.19"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.20">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C71721">Find Clinical Trials for Olaparib</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2014-12-31</DateFirstPublished><DateLastModified>2025-01-02</DateLastModified></DrugInformationSummary>
